TY - JOUR
T1 - Survival after recurrence following surgical resected non-small cell lung cancer
T2 - A multicenter, prospective cohort study
AU - Kyushu University Lung Surgery Study Group Japan
AU - Takenaka, Tomoyoshi
AU - Yano, Tokujiro
AU - Yamazaki, Koji
AU - Okamoto, Tatsuro
AU - Hamatake, Motoharu
AU - Shimokawa, Mototsugu
AU - Mori, Masaki
N1 - Funding Information:
The authors thank Japan Medical Communications (https://www.japan-mc.co.jp) for editing drafts of this report. Kyushu University Lung Surgery Study Group Japan Members: Kohno, MD, PhD, Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Gouji Toyokawa, MD, PhD, Department of Surgery, Fukuoka National Hospital, Fukuoka, Japan; Tsukihisa Yoshida, MD, PhD, Department of Thoracic Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan; Kensaku Ito, MD, PhD, Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan; Naoko Miura, MD, PhD, Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan; Hidenori Kouso, MD, PhD, Department of General Thoracic Surgery, National Hospital Organization, Oita Medical Center, Oita, Japan; Taro Ohba, MD, PhD, Department of Thoracic Surgery, Oita Red Cross Hospital, Oita, Japan; Atsushi Osoegawa, MD, PhD, Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan; Seiichi Fukuyama, MD, PhD, Department of General Thoracic Surgery, National Hospital Organization, Beppu Medical Center, Beppu, Japan; Takuro Kometani, MD, PhD, Department of Surgery, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Hiroshima, Japan; Tetsuzo Tagawa, MD, PhD, Department of Thoracic Surgery and Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan; Fumihiro Shoji, MD, PhD, Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan; Masafumi Yamaguchi, MD, PhD, Department of Thoracic Surgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Shuichi Tsukamoto, MD, PhD, Department of Thoracic Surgery, Steel Memorial Yawata Hospital, Kitakyushu, Japan; Genkichi Saito, MD, PhD, Department of Surgery, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan; Yasuro Fukuyama, MD, PhD, Department of Thoracic Surgery, Nakatsu Municipal Hospital, Nakatsu, Japan; Mitsuhiro Takenoyama, MD, PhD, Department of Thoracic Surgery, Matsuyama Red Cross Hospital, Matsuyama, Japan; Hitoshi Ueda, MD, PhD, Department of Surgery, Fukuoka National Hospital, Fukuoka, Japan; and Sadanori Takeo, MD, PhD, Department of Thoracic Surgery and Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/6
Y1 - 2022/6
N2 - Objectives: The optimal treatment for recurrent non–small cell lung cancer (NSCLC) has not been standardized. In this prospective cohort study, we evaluated post-recurrence survival (PRS) after treatment of recurrent NSCLC and identified prognostic factors after recurrence. Methods: This multicenter prospective cohort study was conducted in 14 hospitals. The inclusion criteria for this study were patients with recurrence after radical resection for NSCLC. Information about the patient characteristics at recurrence, tumor-related variables, primary surgery, and treatment for recurrence was collected. After registration, follow-up data, such as treatment and survival outcomes, were obtained every 3 months. Results: From 2010 to 2015, 505 cases were enrolled, and 495 cases were analyzed. As initial treatment for recurrence, 263 patients (53%) received chemotherapy, 46 (9%) received chemoradiotherapy, 98 (20%) had definitive radiotherapy, 14 (3%) received palliative radiotherapy, and 31 (6%) underwent surgical resection. The remaining 43 patients (9%) received supportive care. The median PRS and 5-year survival rates for all cases were 30 months and 31.9%, respectively. The median PRS according to the initial treatment was as follows: supportive care, 8 months; palliative radiotherapy, 16 months; definitive radiotherapy, 30 months; chemotherapy, 31 months; chemoradiotherapy, 35 months; and surgery, not reached. A multivariate analysis showed that the age, gender, performance status, histology presence of symptoms, duration from primary surgery to recurrence, and number of recurrent foci were independent prognostic factors for PRS. Conclusions: The PRS of patients with recurrent NSCLC was different depending on the patient's background characteristics and initial treatment for recurrence.
AB - Objectives: The optimal treatment for recurrent non–small cell lung cancer (NSCLC) has not been standardized. In this prospective cohort study, we evaluated post-recurrence survival (PRS) after treatment of recurrent NSCLC and identified prognostic factors after recurrence. Methods: This multicenter prospective cohort study was conducted in 14 hospitals. The inclusion criteria for this study were patients with recurrence after radical resection for NSCLC. Information about the patient characteristics at recurrence, tumor-related variables, primary surgery, and treatment for recurrence was collected. After registration, follow-up data, such as treatment and survival outcomes, were obtained every 3 months. Results: From 2010 to 2015, 505 cases were enrolled, and 495 cases were analyzed. As initial treatment for recurrence, 263 patients (53%) received chemotherapy, 46 (9%) received chemoradiotherapy, 98 (20%) had definitive radiotherapy, 14 (3%) received palliative radiotherapy, and 31 (6%) underwent surgical resection. The remaining 43 patients (9%) received supportive care. The median PRS and 5-year survival rates for all cases were 30 months and 31.9%, respectively. The median PRS according to the initial treatment was as follows: supportive care, 8 months; palliative radiotherapy, 16 months; definitive radiotherapy, 30 months; chemotherapy, 31 months; chemoradiotherapy, 35 months; and surgery, not reached. A multivariate analysis showed that the age, gender, performance status, histology presence of symptoms, duration from primary surgery to recurrence, and number of recurrent foci were independent prognostic factors for PRS. Conclusions: The PRS of patients with recurrent NSCLC was different depending on the patient's background characteristics and initial treatment for recurrence.
UR - http://www.scopus.com/inward/record.url?scp=85129925100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129925100&partnerID=8YFLogxK
U2 - 10.1016/j.xjon.2022.03.004
DO - 10.1016/j.xjon.2022.03.004
M3 - Article
AN - SCOPUS:85129925100
SN - 2666-2736
VL - 10
SP - 370
EP - 381
JO - JTCVS Open
JF - JTCVS Open
ER -
